Therefore, our results could be translated into a novel therapeutic approach for skin-hardening diseases that targets mechanically regulated β1 integrin or ERK/PI3K/Akt pathway, as described in this study, to achieve better outcomes. Here, AKT1 is linked to glycogen storage disease VI.